In conclusion, the remarkable antitumor efficacy of BSA1‐SeNPs, coupled with their ability to modulate the immune microenvironment by enhancing CD8+ T cell activation and reducing immunosuppressive cell populations, underscores their promising role in cancer immunotherapy as a multifaceted therapeutic agent. The gene discussed is CD8A; the disease is cancer.